--(BUSINESS WIRE)--Eyenuk, Inc., headquartered in Los Angeles, California, is an AI diagnostic company focused on quickly and accurately identifying patients suffering from potentially blinding eye diseases and chronic diseases at the point of care. Using computer vision and machine learning expertise, the company is developing a portfolio of products based on its proprietary retinal image analysis technology combined with deep learning to identify and track the progression of diseases including diabetic retinopathy, glaucoma, age-related macular degeneration, risk of stroke, cardiovascular risk, and Alzheimer’s disease. EyeArt™ development was partially supported by prestigious National Eye Institute (NEI/NIH) grants (EB013585, EY026864, EY027241). EyeArt™ has received CE Marking and Health Canada approval, and is commercially available in the European Union and in Canada. In the United States, EyeArt™ is limited by federal law to investigational use only and is not available for sale. For more information, visit www.eyenuk.com.
Company: | Eyenuk, Inc. | |
Headquarters Address: | 5850 Canoga Ave., Suite 250 | |
Los Angeles, CA 91367 | ||
Main Telephone: |
760-687-6740 |
|
Website: | ||
Type of Organization: | Private | |
Industry: | Medical Devices | |
Key Executives: | VP, Global BD, Corporate Alliances: Kevin Skol | |
CEO: Kaushal Solanki | ||
Head of Development: Greg Russell | ||
Investor Relations | ||
Contact: | Kevin Skol | |
Phone: |
818-835-3585 |
|
Email: | ||